Acorda Therapeutics (ACOR) Scheduled to Post Earnings on Monday

Acorda Therapeutics (NASDAQ:ACOR) will be posting its quarterly earnings results before the market opens on Monday, February 12th. Analysts expect Acorda Therapeutics to post earnings of $1.00 per share for the quarter.

Shares of Acorda Therapeutics (NASDAQ ACOR) opened at $25.30 on Monday. Acorda Therapeutics has a twelve month low of $13.60 and a twelve month high of $33.00. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.77 and a quick ratio of 2.40. The company has a market cap of $1,182.70, a PE ratio of -20.91 and a beta of 1.63.

Several equities research analysts have recently commented on the stock. Raymond James Financial lowered shares of Acorda Therapeutics from a “market perform” rating to an “underperform” rating and boosted their price target for the company from $7.00 to $13.00 in a report on Thursday, November 16th. Zacks Investment Research lowered shares of Acorda Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. JPMorgan Chase & Co. set a $24.00 price target on shares of Acorda Therapeutics and gave the company a “hold” rating in a report on Tuesday, October 31st. HC Wainwright restated a “buy” rating and issued a $31.00 price target (down previously from $34.00) on shares of Acorda Therapeutics in a report on Wednesday, January 17th. Finally, Oppenheimer assumed coverage on shares of Acorda Therapeutics in a report on Thursday, November 9th. They issued a “market perform” rating and a $27.00 price target for the company. Four research analysts have rated the stock with a sell rating, ten have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $21.35.

In other Acorda Therapeutics news, insider David Lawrence sold 31,000 shares of the business’s stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $27.58, for a total transaction of $854,980.00. Following the sale, the insider now owns 5,275 shares of the company’s stock, valued at approximately $145,484.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Burkhard Blank sold 11,050 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $20.53, for a total transaction of $226,856.50. Following the sale, the insider now directly owns 33,150 shares in the company, valued at approximately $680,569.50. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: “Acorda Therapeutics (ACOR) Scheduled to Post Earnings on Monday” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/02/05/acorda-therapeutics-acor-scheduled-to-post-earnings-on-monday.html.

About Acorda Therapeutics

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Earnings History for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply